OncoSil FDA designation & PanCO study success

"OncoSil Medical has achieved key milestones, including CE Marking, US FDA breakthrough device designation, and successful completion of the PanCO Study, demonstrating the device’s safety and efficacy. 33% of patients treated with OncoSil became eligible for surgical resection, and 57% saw at least a 50% reduction in tumour volume."

I saw the above on this article - Impressive numbers. The fact that 33% of patients became eligible for surgical resection after using OncoSil's device is a BIG deal. It shows the real-world impact this treatment is having. Plus, a 50% reduction in tumour volume for over half the patients? That is a significant achievement in the fight against pancreatic cancer.